Show simple item record

dc.contributor.authorSalerno, Christopher T
dc.contributor.authorHayward, Christopher
dc.contributor.authorHall, Shelley
dc.contributor.authorGoldstein, Daniel
dc.contributor.authorSaeed, Diyar
dc.contributor.authorSchmitto, Jan
dc.contributor.authorKaczorowski, David
dc.contributor.authorMolina, Ezequiel
dc.contributor.authorZimpfer, Daniel
dc.contributor.authorTsui, Steven
dc.contributor.authorSoltesz, Edward
dc.contributor.authorPham, Duc Thin
dc.contributor.authorMokadam, Nahush A
dc.contributor.authorKilic, Arman
dc.contributor.authorDavis, Erin
dc.contributor.authorFeller, Erika
dc.contributor.authorLorts, Angela
dc.contributor.authorSilvestry, Scott
dc.contributor.authorSlaughter, Mark S
dc.contributor.authorPotapov, Evgenij
dc.contributor.authorAtluri, Pavan
dc.contributor.authorCowger, Jennifer
dc.contributor.authorPagani, Francis D
dc.date.accessioned2022-05-23T10:59:56Z
dc.date.available2022-05-23T10:59:56Z
dc.date.issued2022-03-18
dc.identifier.urihttp://hdl.handle.net/10713/18958
dc.description.abstractThe HeartWare HVAD System (Medtronic) is a durable implantable left ventricular assist device that has been implanted in approximately 20,000 patients worldwide for bridge to transplant and destination therapy indications. In December 2020, Medtronic issued an Urgent Medical Device Communication informing clinicians of a critical device malfunction in which the HVAD may experience a delay or failure to restart after elective or accidental discontinuation of pump operation. Moreover, evolving retrospective comparative effectiveness studies of patients supported with the HVAD demonstrated a significantly higher risk of stroke and all-cause mortality when compared with a newer generation of a commercially available durable left ventricular assist device. Considering the totality of this new information on HVAD performance and the availability of an alternate commercially available device, Medtronic halted the sale and distribution of the HVAD System in June 2021. The decision to remove the HVAD from commercial distribution now requires the use of the HeartMate 3 left ventricular assist system (Abbott, Inc) if a patient previously implanted with an HVAD requires a pump exchange. The goal of this document is to review important differences in the design of the HVAD and HeartMate 3 that are relevant to the medical management of patients supported with these devices, and to assess the technical aspects of an HVAD-to-HeartMate 3 exchange. This document provides the best available evidence that supports best practices.en_US
dc.description.urihttps://doi.org/10.1016/j.athoracsur.2021.11.078en_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofAnnals of Thoracic Surgeryen_US
dc.rightsCopyright © 2022 The Society of Thoracic Surgeons, The American Association for Thoracic Surgery, and European Association for Cardio-Thoracic Surgery. Published by Elsevier Inc. All rights reserved.en_US
dc.titleHVAD to HeartMate 3 Left Ventricular Assist Device Exchange: Best Practices Recommendations.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.athoracsur.2021.11.078
dc.identifier.pmid35341592
dc.source.journaltitleThe Annals of thoracic surgery
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record